GlassScriptPhysician profile
Vaseem S Akhtar
NPI 1568660561
$3,355.69
in general payments reported to CMS, 2019-2025
27 companies · $736 in 2025
The $736 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2020: $545 · 2021: $258 · 2022: $275 · 2023: $442 · 2024: $443 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,521 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,521.43 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,066.80 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $502.92 | 2019-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $322.33 | 2019-2025 | Tagrisso |
| Genzyme Corporation | $299.47 | 2020-2025 | |
| Janssen Biotech, INC. | $198.81 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Array Biopharma INC | $139.61 | 2020-2025 | Mektovi, Braftovi, Lorbrena |
| Seagen INC. | $99.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $88.76 | 2019-2024 | |
| Celgene Corporation | $79.36 | 2022-2025 | Reblozyl |
| Astellas Pharma US INC | $73.78 | 2022-2025 | Xtandi |
| E.R. Squibb & Sons, L.L.C. | $69.90 | 2019 | |
| Daiichi Sankyo INC. | $60.56 | 2022-2023 | Enhertu |
| Incyte Corporation | $49.65 | 2025 | Monjuvi, Zynyz |
| Sobi, INC | $44.81 | 2022-2023 | |
| Abbvie INC. | $41.17 | 2020-2023 | Venclexta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $26.10 | 2023 | Besremi |
| Fennec Pharmaceuticals, INC. | $26.01 | 2024 | Pedmark |
| Mylan Institutional INC. | $21.93 | 2019 | |
| Taiho Oncology, INC. | $20.35 | 2024 | |
| Eisai INC. | $19.81 | 2023 | |
| Helsinn Therapeutics (U.S.), INC. | $18.82 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.63 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.01 | 2020 | |
| Shire North American Group INC | $13.62 | 2019 | |
| Kyowa Kirin, INC. | $13.08 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.22 | 2021 | |
| Dova Pharmaceuticals | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vaseem Akhtar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.